Register
Login:
Share:
Email Facebook Twitter

Add Reneuron to quick picks

Reneuron Share Price (RENE)



Share Price Information for Reneuron (RENE)


Share Price: 3.75Bid: 3.50Ask: 4.00Change: -0.125 (-3.23%)Faller - Reneuron
Spread: 0.50Spread as %: 14.29%Open: 3.875High: 3.875Low: 3.75Yesterday’s Close: 3.875

Reneuron Group Plc Ord 1P

Reneuron is listed in the FTSE AIM All-Share
Reneuron is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
3.75

Share Price SpacerBid
3.50

Share Price SpacerAsk
4.00

Share Price SpacerChange
-3.23%-0.125

Share Price SpacerVolume
1,997,618

Share Price SpacerOpen
3.875

Share Price SpacerHigh
3.875

Share Price SpacerLow
3.75

Share Price SpacerClose
3.875

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 1,788.83m £67.08m 100,000

52 Week High 4.13 52 Week High Date 26-NOV-2014
52 Week Low 2.71 52 Week Low Date 23-DEC-2013

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
25 1,648,841 348,777 -7.500 -0.50 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

27-Nov-14
16:07:33
3.775
38,808
Buy* 
3.50
4.00
1,465
Trade Type:
Ordinary

27-Nov-14
15:34:37
3.775
6,306
Buy* 
3.50
4.00
238.05
Trade Type:
Ordinary

27-Nov-14
14:57:30
3.505
2,831
Sell* 
3.50
4.00
99.23
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Reneuron trades >>

Directors Deals for Reneuron (RENE)
Trade DateActionNotifierPriceCurrencyAmountHolding
25-Jul-14Buy
Trade Notifier Information for ReNeuron Group
John Sinden held the position of Director at ReNeuron Group at the time of this trade.
 John Sinden
3.5GBX93,8922305794
25-Jul-14Buy
Trade Notifier Information for ReNeuron Group
Michael Hunt held the position of CEO at ReNeuron Group at the time of this trade.
 Michael Hunt
3.5GBX93,8921346915
07-Aug-13Placing
Trade Notifier Information for ReNeuron Group
Bryan Morton held the position of Non-Executive Chairman at ReNeuron Group at the time of this trade.
 Bryan Morton
2.5GBX800,0001015909
View more Reneuron directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 21:24
Arbitrage
latest Corporate presentation:
3.75
No Opinion

http://vm.buchanan.uk.com/_vti_bin/shtml.dll/2014/reneuron171114/registration.htm
Today 07:46
Arbitrage
TeamWales: historical rns info
3.88
No Opinion

http://www.investegate.co.uk/Index.aspx?searchtype=3&words=rene
Wed 23:03
TeamWales
RE: Watch list
3.88
No Opinion

Thanks for clearing that up for me Fred. I'll be taking a position shortly.
Wed 18:51
Fredd1eboy
RE: Watch list
3.88
Strong Buy

Hi Teamwales. Quick reply... Reneuron will be manufacturing their own stem cells in just over one year. The cost of the dose will come right down. Volume manufacture of a successful drug will bring it down further. Reneuron is currently financed through to well into 2016 at which time successful phase 111 trials will attract big partners.Also three treatment lines will be well on the way to fruition. All in all a much safer gamble than we were at three years ago when the sp was much higher. Best wishes. Freddie
Wed 18:36
Fredd1eboy
RE: Hi boba
3.88
Strong Buy

Hi Chewise. Theres the UK stem cell summit next week and John Sinden is giving an update on Ren001. If I were a gambling man, not wishing to jump the gun, a few scans of before and after could tell an interesting story. In any event, in my book, his presentation is likely interest the media, investors and very likely provide an opportunity for the sp to rise. Hopefully he may also update the audience on his exosome research which is linked to that which has been seen in stem cell neural activity. Interviews with former patients could also be on the cards, as its happened before. All in all a good opportunity for advancement in sp Sorry for the scrappy reply but in a rush. Best wishes. Freddie
Wed 17:19
TeamWales
Watch list
3.88
No Opinion

Been observing this share for quite some time. Looking to get involved however I do have some doubts regarding finances. Obviously from the PISCES trail things are looking good, but the cost for each patient to receive stem cell treatment is quite high. Is this financial viable, and would clients be willing to pay to have this?

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Reneuron (RENE) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.